“These results reactivate the option of clinical trials with Denosumab in breast cancer selected patients”, says Eva González-Suarez, CNIO and IDIBELL researcher and lead author.
These are the results of an international study with the participation of the Catalan Institute of Oncology (ICO), the Bellvitge Biomedical Research Institute (IDIBELL) and the Valencian Institute of Oncology (IVO) and in which they make a comparison between the two techniques.
Through a mobile device, HearO™ makes it possible to predict possible complications in patients with heart failure through speech, detect disease-related fluid accumulation and alert the doctor before hospitalization
Scientists from IDIBELL and the University of Barcelona identify how HERC1 deficiency unbalances bone homeostasis, causing osteopenia. These results identify potential therapeutic targets for individuals with bone diseases and HERC1 deficiency.
To establish whether oropharyngeal cancer was related to the human papillomavirus, the recomendation is do it through the p16 protein detection.
Now a study from IDIBELL published in The Lancet Oncology has shown that not all p16-positive oropharyngeal cancers are caused by the virus.
The IDIBELL Bacterial Epidemiology research group has published a paper on the adaptation of Haemophilus spp in patients with chronic obstructive pulmonary disease (COPD) and prolonged treatment with azithromycin.
The results, published in Antioxidant and Obesity scientific journals, show that the intake of most polyphenols is associated with maintenance or a lower weight gain, highlighting those polyphenols present in fruits, vegetables, olive oil, tea, cocoa, or cereals integral.
The Association Jut against cancer is a recently created association from Sant Boi de Llobregat that raises funds through different solidarity, sporting and creative initiatives in which the patients participate.
The results of the TRITON3 study show that patients with prostate cancer treated with a PARP inhibitor, called Rucaparib, take almost twice as long for the disease to progress than those treated with conventional chemotherapy.
The Govern approved today the awarding of the Josep Trueta medals and plaques to outstanding professionals and entities in the health field. Among the award-winning entities is the Bellvitge University Hospital, for its work as a reference center of maximum complexity for 2 million people. Likewise, one of the individual medals has been for Dr. Mònica Povedano, a neurologist at Hospital de Bellvitge and IDIBELL researcher.
